Rob Scoffin, CEO, and Matthew Habgood, Principal Computational Chemistry Developer at Cresset, discuss the role of AI/ML in advancing screening methods by utilising virtual screening (VS) approaches to process compound libraries on an ultra-large scale. Drug discovery is a complex process that relies on designing and filtering potential drug candidates through a funnel until a […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!